Integrity Applications (OTC: IGAP) is a medical device company focused on the design, development and commercialization of non-invasive glucose monitoring devices for use by people with diabetes. Integrity Applications operates primarily through its wholly owned Israeli subsidiary, A.D. Integrity Applications, … Continue reading →

Relmada Therapeutics (OTC: RLMD), a clinical-stage biopharmaceutical company, develops novel versions of proven drug products combined with new chemical entities that potentially address areas of high unmet medical need in the treatment of pain. The company has four lead products … Continue reading →

Antibe Therapeutics (OTC: ATBPF) develops medicines for pain and inflammation. Antibe’s technology involves linking a hydrogen sulfide-releasing molecule to an existing drug to produce a patented, improved medicine. Antibe’s lead drug ATB-346 targets the global need for a safer non-steroidal … Continue reading →

Q BioMed (OTC: QBIO) is a biomedical acceleration and development company that is focused on acquiring undervalued biomedical assets. Q BioMed is dedicated to providing these target assets, strategic resources, developmental support, and expansion capital to accelerate development and, ultimately, … Continue reading →

General Employment Enterprises, Inc. (NYSE: JOB) provides specialized staffing solutions, operating in two industry segments: providing professional staffing services and solutions in the information technology, engineering, finance and accounting specialties and light industrial staffing services through the names of General … Continue reading →

PCM, Inc. (NASDAQ: PCMI) (formerly known as PC Mall, Inc.) is a technology solutions provider to businesses, government and educational institutions and individual consumers. The company markets its products, services and solutions through a 700+ sales force, field service teams, … Continue reading →

Pulmatrix NASDAQ: PULM) is a clinical stage biopharmaceutical company developing innovative inhaled therapies to address serious pulmonary disease  using its clinically validated, proprietary iSPERSE technology. The company’s PUR0200 is a branded generic in clinical development for chronic obstructive pulmonary disease. … Continue reading →

BioRestorative Therapies (OTC: BRTX) develops therapeutic products primarily using adult stem cells. The company’s lead cell therapy candidate is formulated from autologous cultured mesenchymal stem cells for the non-surgical treatment of chronic lumbar disc disease. The treatment is intended for patients … Continue reading →

CEL-SCI (NYSE: CVM) is primarily focused on R&D to improve the treatment of cancer and other diseases by utilizing the immune system, the body’s natural defense system. Its lead investigational therapy, Multikine, is currently being studied in a pivotal global … Continue reading →

Apivio Systems (OTC: APVVF) is a Canadian technology company engaged in the design, development, marketing, and sale of communications equipment and software. It has a wholly owned Korean subsidiary with a history of supplying VoIP telephone equipment and other products … Continue reading →